RxDoctor Payments DataLook up a doctor →

Ronald Tutrone, MD

Urology · Baltimore, MDNPI 1265495204

Payments from drug & device makers

$18,133,687in general payments, 2019–2025

Across 2,222 payments — averaging $8160.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medivation LLC.$8.2M
  • Pfizer$5.3M
  • AstraZeneca$1.1M
  • Janssen Research & Development, LLC$841K
  • Dendreon Pharmaceuticals LLC$567K
  • Merck$493K
  • plus $1.7M from 51 others
$83,109in research payments, 2019–2025

Across 36 payments — averaging $2308.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dendreon Pharmaceuticals LLC$48K
  • Pfizer$23K
  • Novartis$7K
  • Eli Lilly$2K
  • Astellas Pharma Global Development$2K

What the payments were for

  • Consulting fees$26,85030%
  • Speaking & faculty fees$44,04750%
  • Travel & lodging$7,0918%
  • Food & beverage$10,71212%
  • Education$370%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,133,687 in reported general payments places this provider in the 95th percentile of 274 urology providers in Maryland.

See all urology providers in Maryland

Medicare billing

Part B allowed, 2024
$211,423
Medicare patients
340
Services billed
6,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide29$407,927
ErleadaApalutamide25$369,435
NubeqaDarolutamide18$234,568
OrgovyxRelugolix48$141,772
Abiraterone Acetate28$69,554
MyrbetriqMirabegron27$29,092
GemtesaVibegron22$16,878
Testosterone23$5,774
Finasteride306$5,479
Tamsulosin Hcl243$4,873
Alfuzosin Hcl ErAlfuzosin Hcl93$3,699
Tadalafil27$3,106
Tolterodine Tartrate ErTolterodine Tartrate18$2,193
Potassium Citrate ErPotassium Citrate19$2,060
Desmopressin Acetate32$1,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$13,900$437,02056 claims
Johnson & JohnsonErleada$998$369,43525 claims
BayerNubeqa$393,514$234,56818 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$48,562$158,64970 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$39$69,55428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Maryland.

Other urology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →